VANDA PHARMACEUTICALS INC. Cash and Cash Equivalents
VANDA PHARMACEUTICALS INC. (VNDA) had Cash and Cash Equivalents of $55.88 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-08-06
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $55.88M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $54.03M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $84.85M.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $70.02M.
| Period end | Cash and Cash Equivalents, at Carrying Value |
|---|---|
| 2026-06-30 | $55.88M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $54.03M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $84.85M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $70.02M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $80.98M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $111.80M 10-Q · filed 2026-05-07 |
| 2024-12-31 | $102.32M 10-K · filed 2026-02-12 |
| 2024-09-30 | $100.50M 10-Q · filed 2025-10-30 |
| 2024-06-30 | $102.95M 10-Q · filed 2025-07-31 |
| 2024-03-31 | $125.16M 10-Q · filed 2025-05-08 |
| 2023-12-31 | $135.82M 10-K · filed 2025-02-14 |
| 2023-09-30 | $183.19M 10-Q · filed 2024-11-07 |
| 2023-06-30 | $150.03M 10-Q · filed 2024-08-01 |
| 2023-03-31 | $354.17M 10-Q · filed 2024-05-09 |
| 2022-12-31 | $135.03M 10-K · filed 2024-02-08 |
| 2022-09-30 | $49.40M 10-Q · filed 2023-11-09 |
| 2022-06-30 | $58.23M 10-Q · filed 2023-07-28 |
| 2022-03-31 | $66.93M 10-Q · filed 2023-05-03 |
| 2021-12-31 | $52.07M 10-K · filed 2023-02-09 |
| 2021-09-30 | $50.52M 10-Q · filed 2022-11-03 |
| 2021-06-30 | $57.24M 10-Q · filed 2022-08-04 |
| 2021-03-31 | $72.13M 10-Q · filed 2022-05-06 |
| 2020-12-31 | $61.03M 10-K · filed 2022-02-24 |
| 2020-09-30 | $56.97M 10-Q · filed 2021-11-04 |
| 2020-06-30 | $95.31M 10-Q · filed 2021-07-29 |
| 2020-03-31 | $64.95M 10-Q · filed 2021-05-06 |
| 2019-12-31 | $45.07M 10-K · filed 2021-02-11 |
| 2019-09-30 | $39.21M 10-Q · filed 2020-10-29 |
| 2019-06-30 | $46.54M 10-Q · filed 2020-08-06 |
| 2019-03-31 | $34.38M 10-Q · filed 2020-05-07 |
| 2018-12-31 | $61.01M 10-K · filed 2020-02-26 |
| 2018-09-30 | $60.78M 10-Q · filed 2019-11-07 |
| 2018-06-30 | $60.89M 10-Q · filed 2019-08-01 |
| 2018-03-31 | $155.29M 10-Q · filed 2019-05-03 |
| 2017-12-31 | $33.63M 10-K · filed 2019-02-19 |
| 2017-09-30 | $22.59M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $14.23M 10-Q · filed 2017-08-03 |
| 2017-03-31 | $20.11M 10-Q · filed 2017-05-03 |
| 2016-12-31 | $40.43M 10-K · filed 2018-02-15 |
| 2016-09-30 | $32.77M 10-Q · filed 2017-11-08 |
| 2016-06-30 | $23.19M 10-Q · filed 2017-08-03 |
| 2016-03-31 | $38.74M 10-Q · filed 2017-05-03 |
| 2015-12-31 | $50.84M 10-K · filed 2018-02-15 |
| 2015-09-30 | $46.79M 10-Q · filed 2016-11-03 |
| 2015-06-30 | $48.34M 10-Q · filed 2016-07-28 |
| 2015-03-31 | $32.81M 10-Q · filed 2016-05-05 |
| 2014-12-31 | $60.90M 10-K · filed 2018-02-15 |
| 2014-09-30 | $15.31M 10-Q · filed 2015-11-04 |
| 2014-06-30 | $16.99M 10-Q · filed 2015-07-31 |
| 2014-03-31 | $43.26M 10-Q · filed 2015-05-07 |
| 2013-12-31 | $64.76M 10-K · filed 2017-02-17 |
| 2013-09-30 | $142.17M 10-Q · filed 2014-10-27 |
| 2013-06-30 | $103.63M 10-Q · filed 2014-08-08 |
| 2013-03-31 | $109.93M 10-Q · filed 2014-05-08 |
| 2012-12-31 | $88.77M 10-K · filed 2016-02-12 |
| 2012-09-30 | $104.52M 10-Q · filed 2013-11-08 |
| 2012-06-30 | $94.39M 10-Q · filed 2013-07-31 |
| 2012-03-31 | $108.09M 10-Q · filed 2013-05-10 |
| 2011-12-31 | $87.92M 10-K · filed 2015-03-13 |
| 2011-09-30 | $60.33M 10-Q · filed 2012-11-08 |
| 2011-06-30 | $50.39M 10-Q · filed 2012-08-03 |
| 2011-03-31 | $52.52M 10-Q · filed 2012-05-09 |
| 2010-12-31 | $42.56M 10-K · filed 2014-02-25 |
| 2010-09-30 | $102.47M 10-Q · filed 2011-11-07 |
| 2010-06-30 | $145.65M 10-Q · filed 2011-08-05 |
| 2009-12-31 | $205.29M 10-K · filed 2013-02-26 |
| 2008-12-31 | $39.08M 10-K · filed 2012-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |